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Abstract 1 
 2 
 3 
The abnormality of viral core structure seen in vif-defective HIV-1 grown in PBMCs has 4 
suggested a role for Vif in viral morphogenesis. Using an in-vivo mammalian two hybrid 5 
assay the interaction between Vif and the precursor (Pr55GAG) of the virion nucleocapsid 6 
proteins has been analysed. This revealed the amino terminal (aa 1-22) and central (aa 70-100) 7 
regions of Vif to be essential for its interaction with Pr55GAG but deletion of the carboxy 8 
terminal (aa 158-192) region of the protein had only a minor effect on its interaction. Initial 9 
deletion studies carried out on Pr55GAG showed that a 35 amino acid region of the protein 10 
bridging the MA(p17)-CA(p24) junction was essential for its ability to interact with Vif. Site 11 
directed mutagenesis of a conserved tryptophan (Trp21) near the amino terminus of Vif 12 
showed it to be important for the interaction with Pr55GAG. By contrast mutagenesis of the 13 
highly conserved YLAL residues forming part of the BC-box motif, shown to be important in 14 
Vif promoting degradation of APOBEC3G/3F, had little or no effect on the Vif - Pr55GAG 15 
interaction. 16 
  17 
 3 
Introduction 1 
 2 
In addition to the canonical gag, pol and env genes found in all retroviruses, the human 3 
immunodeficiency virus (HIV-1) in common with most other lentiviruses encodes six 4 
regulatory proteins (Tat, Rev, Vpr, Vif, Nef and Vpu) usually referred to as accessory proteins. 5 
Of these Vif is encoded by all lentiviruses with the exception of equine infectious anaemia 6 
virus (EIAV) 29 and in several animal models it has been shown to be essential for virus 7 
infection 10, 17. In HIV-1, Vif is a 23KDa basic protein that is required in a cell type dependent 8 
fashion for the production of infectious virus 21. Thus most CD4+ continuous cell lines give 9 
normal virus yields when infected with vif deleted virus and are consequently said to be 10 
permissive, whereas others such as H9 cells and crucially PBMCs, the normal in-vivo host 11 
cells for HIV, give greatly reduced virus yields of Vif minus virus and are termed non-12 
permissive or restrictive 12, 14, 15. Studies on heterokaryons made between permissive and 13 
restrictive cells showed that the restrictive phenotype was dominant indicating the presence in 14 
restrictive cells of an inhibitor of virus replication 25, 34. In an elegant study this inhibitor was 15 
identified as a member of the APOBEC family of cytidine deaminases 32. A series of 16 
subsequent studies have shown that in the absence of Vif, APOBEC3G/3F expressed in 17 
restrictive cells is packaged into virus particles and leads to hypermutation of the viral 18 
genome following deamination of cytidine to uridine (C → U) during synthesis of minus 19 
strand viral cDNA 18, 26, 40, 41. Despite the recent focus on the role of Vif in blocking the action 20 
of APOBEC, earlier studies on Vif deleted virus produced from restrictive cell lines revealed 21 
the virions to have malformed viral core structures pointing to a possible role for Vif in 22 
modulating the processing by the viral protease of the Pr55GAG precursor that leads to the 23 
formation of the viral nucleocapsid 4, 6, 19. However attempts to demonstrate a direct role for 24 
Vif in the morphogenesis of virus particles has produced conflicting results 5, 13. In a previous 25 
study examining the sequence of the vif gene in virus isolated from patients undergoing 26 
treatment with antiviral drugs directed at the viral protease we were able to show a linkage 27 
between specific amino acids at a number of positions in Vif and the development of 28 
resistance to protease inhibitors 1. These data are again suggestive of a role for Vif in 29 
modulating the action of protease in processing of the Pr55GAG precursor. In the present study 30 
we have made use of a mammalian two-hybrid assay 31, 37 to screen for direct interactions in-31 
vivo between Vif and both the viral protease and its substrate Pr55GAG. 32 
  33 
 4 
Materials and Methods 1 
 2 
(i) Plasmids: The pM and pVP16 mammalian two-hybrid vectors from the  3 
‘MatchmakerTM’ system (Clontech) were used to generate fusion protein constructs for use in 4 
two-hybrid assays. Two reporter plasmids were employed, pG5CAT (Clontech) which 5 
expresses Chloramphenicol acetyl transferase (CAT) under the control of a Gal4 responsive 6 
promoter and pUAST-hrGFP-neo which expresses green fluorescent protein (GFP) also under 7 
the control of a Gal4 responsive promoter. The latter plasmid was obtained from Dr K.T. 8 
Chung (University of Warwick). 9 
The vif sequences used in constructing two hybrid fusion vectors were generated by PCR 10 
from a cDNA sub-clone carrying the vif gene generated from the HXB2 isolate of HIV-1 7. 11 
All cDNA clones whose derivation involved PCR were re-sequenced to ensure that no 12 
adventitious mutations had been introduced during PCR amplification. The coding sequence 13 
for Pr55GAG  was obtained by sub-cloning from a cDNA clone of the BH-10 isolate of HIV-1 14 
11 and the coding sequence for the viral protease was also obtained by sub-cloning from a BH-15 
10 derived DNA clone  2. 16 
 17 
(ii) Propagation and Transfection of Mammalian Cells: The COS-1 line of African green 18 
monkey kidney cells 16 was used for all two hybrid assays. The cells were grown in Glasgow 19 
modified MEM supplemented with 10% foetal calf serum. For use in transfection experiments 20 
cells were plated in 12-well tissue culture dishes and used at ~80% confluency. Each well of 21 
cells was transfected with a mixture containing 1µgm of each of the three plasmids and 3.5µl 22 
of Lipofectaine 2000 (Invitrogen). In all experiments cells were transfected in parallel with a 23 
plasmid expressing GFP constitutively from the immediate early promoter of cytomegalovirus 24 
to allow transfection efficiency to be measured so that comparability between experiments 25 
could be ensured. 26 
 27 
(iii) Mammalian Two-Hybrid Assays: Two reporter genes were employed in this study. 28 
GFP has the advantage that it can be simply assayed by UV microscopy of live cells but its 29 
limitation is that it gives a largely qualitative plus-minus result. By contrast the CAT reporter 30 
requires the preparation of cell extracts and therefore assaying it is more labour intensive but 31 
it has the advantage of giving a quantitative measure of reporter gene expression. Conseqently 32 
 5 
in most cases interaction assays were initially scored using the GFP reporter and then the 1 
strength of the interaction assess using the CAT reporter. 2 
GFP expression was assayed in live cells by examining them under a UV microscope at 72 3 
hours after transfection. CAT reporter expression was assayed in cytoplasmic extracts of 4 
transfected cells also made at 72 hours after transfection using a ELISA based CAT assay kit 5 
from Roche as described in the manufacturer’s instructions. 6 
 7 
(iv) GST Pulldown Assays: GST-Vif and GST- Pr55GAG fusions used as ‘bait’ proteins in the 8 
assay were constructed by insertion of the relevant open reading frames into the pET42b 9 
vector (Novagen). After overnight induction of bait protein expression in E.coli (BLR) with 10 
1mM IPTG, cells with lysed by French press and a 30,000g supernatant containing the soluble 11 
GST fusions prepared for binding to glutathione agarose beads for six hours at 40C. After 12 
washing extensively with phosphate buffered saline (PBS) to remove unbound proteins the 13 
beads were used in binding assays. Radio-labelled test proteins were prepared using the TNT 14 
Quick (Promega) coupled transcription-translation system according to the manufacturers 15 
instructions. In all cases the system was primed with a plasmid carrying the ORF of the test 16 
protein inserted downstream of the T7 promoter. 100,000cpm of each test protein was 17 
incubated with either of the two bait proteins bound to glutathione beads in PBS-1% Triton-18 
X-100 for six hours at 40C. After extensive washing with PBS-1% Triton-X-100 the bound 19 
protein was eluted by boiling in 2% SDS-5% β-ME and the retained radioactivity measured 20 
by liquid scintillation counting. 21 
  22 
(v) Mutagenesis: Deletion and site directed mutagenesis of the pVP16-Vif and pM- Pr55GAG 23 
fusion vectors were both carried out using PCR based techniques as previously described 20, 30. 24 
  25 
 6 
Results 1 
 2 
(i) Screening for in-vivo interactions between Vif and Pr55GAG or Protease (PR). 3 
  4 
The GFP reporter was employed to provide a rapid and convenient assay for screening live 5 
cells for evidence of interaction between two-hybrid fusion constructs co-transfected into 6 
COS-1 cells. A clear interaction between Vif and Pr55GAG was detected with fusion constructs 7 
of either protein to both the Gal4 DNA binding domain and the VP16 activation domain (Fig 8 
1). By contrast no evidence of interaction between Vif and PR was seen with either of the PR 9 
fusion constructs generated (Fig1 and results not shown). PR also failed to show any 10 
interaction with Pr55GAG (Fig 1).  11 
 12 
The clear interaction between Vif and Pr55GAG was confirmed in cell free extracts made from 13 
cells co-transfected with the CAT reporter which allowed a more quantitative assessment of 14 
the interaction (Fig 2). 15 
 16 
(ii) Mapping the regions of Vif interacting with Pr55GAG. 17 
 18 
Initial attempts to localise the regions of Vif involved in the interaction with Pr55GAG made 19 
use of three deletion mutants of Vif covering the amino and carboxy terminal regions of the 20 
protein and a central region encompassing amino acids 70-100 (see Fig 3). Two hybrid assays 21 
carried out using these mutants revealed that both the amino terminal 26 amino acids and the 22 
central region of the protein were essential for the interaction whereas loss of the carboxy 23 
terminal 35 amino acids only resulted in an approximately 40% drop in reporter gene 24 
expression which nevertheless remained clearly positive in comparison to the negative 25 
controls. (Fig 4A). The results shown in this and all other figures have been repeated on at 26 
least three occasions and a complete set of illustrative results is shown in each case 27 
 28 
In a previous study on Vif we have reported on the importance of the conserved tryptophan 29 
(Trp) at amino acid 21 to the functioning of Vif to generate infectious virus when propagated 30 
in restrictive cell lines 7. It was therefore of interest to examine the effect on Vif’s interaction 31 
with Pr55GAG of introducing the same mutational changes at amino acid 21 as those examined 32 
in the earlier studies. When this was done there was a striking correspondence between results 33 
 7 
obtained in the two hybrid assay and those found in the earlier study, in that changing the 1 
Trp21 to arginine, isoleucine or tyrosine resulted in a greater than 80% drop in reporter gene 2 
expression whereas substitution with phenyalanine gave wild levels of reporter gene activity 3 
(Fig 4B). 4 
 5 
In an attempt to localise other regions of Vif that might contribute to its interaction with 6 
Pr55GAG attention was focused on the conserved BC-box motif that has been shown to be 7 
crucial to the interaction of Vif with the Cul5-EloBC complex required to induce the 8 
ubiquitin-proteasome based degradation of the APOBEC3G/3F viral inhibitor 28, 39. Site 9 
directed mutagenesis was employed to make single and double amino acid changes in the 10 
highly conserved YLAL region of this motif. However when the mutated Vif was used in the 11 
two hybrid assay there was at most an ~40% reduction in reporter gene expression (Fig 4C) 12 
indicating that this highly conserved motif is not essential for the Vif-Pr55GAG  interaction. 13 
 14 
(iii) Mapping the regions of Pr55GAG interacting with Vif: 15 
 16 
To begin the process of localising the region(s) of Pr55GAG involved in interacting with Vif a 17 
number of deletion mutants of the protein were constructed. These were focused primarily on 18 
the cleavage sites in the protein for the viral protease (see Fig 3). The results obtained when 19 
these mutants were used in two hybrid assays are shown in Table 1. Deletion of the either the 20 
amino terminal or carboxy terminal 35 amino acids, deletion of L1 or deletion of L1 and SP1 21 
from the carboxy terminus of the protein all had no effect on reporter gene expression. By 22 
comparison if either the coding sequence for MA or a 35 amino acid region encompassing the 23 
MA-CA junction were deleted then reporter gene expression was reduced by >80% (Fig 5) 24 
indicating the importance of this region of  Pr55GAG to the interaction with Vif. 25 
 26 
(iv)Validation of mammalian results using in-vitro GST Pull-down assay: 27 
 28 
To validate the protein interactions seen in-vivo with the mammalian two hybrid assay GST 29 
pull-down assay was used. The results obtained with this in-vitro assay (Fig 6) confirmed 30 
those obtained in-vivo, with wild type Vif and the Vif mutant with Phe replacing the Trp at 31 
position 21 both giving a clear interaction with Pr55GAG.  By contrast the Tyr21 substitution 32 
of Vif caused the loss of Pr55GAG interaction (Fig 6). The NSP1 protein of rotavirus which is 33 
 8 
an RNA binding protein also failed to interact with Pr55GAG in this assay (Fig 6) making it 1 
unlikely that the observed Vif- Pr55GAG interaction involved an RNA intermediate. 2 
   3 
 9 
Discussion 1 
 2 
The purpose of the present study was to extend a range of earlier studies 4-6, 13, 19 including our 3 
own 1 which have focused on a role for Vif in the process of viral morphogenesis. The 4 
mammalian two hybrid assay used in this study provided clear evidence of an interaction 5 
between Vif and Pr55GAG in-vivo. This result is in line with an earlier, primarily in-vitro, 6 
study using a GST pull down assay 5. By contrast no evidence of any interaction occurring 7 
between Vif and the protease of HIV-1 was found in the mammalian two hybrid assay which 8 
contradicts results obtained using ELISA assays with HIV proteins expressed in and purified 9 
from E.coli 3. The negative result obtained in the mammalian two hybrid assay does however 10 
need to be treated with some caution as attempts to show an interaction between the viral 11 
protease and its substrate (Pr55GAG), which must occur if only transiently during virion 12 
assembly, were also unsuccessful. 13 
 14 
The initial deletion analysis aimed at localising the region(s) of Vif involved in the interaction 15 
with Pr55GAG showed that the amino terminal region and a central area of Vif  were both 16 
important for this interaction. By contrast deletion of the carboxy terminal 35 amino acids of 17 
Vif produced only a relatively small drop (~40%) in the level of interaction with Pr55GAG as 18 
measured by reporter gene expression in the mammalian two hybrid assay. This last result is 19 
at odds with earlier results using the in-vitro GST pull-down assay where deletion of the 20 
carboxy terminal 22 amino acids of Vif abolished its interaction with Pr55GAG 5. It seems 21 
probable that this discrepancy between the two studies can be attributed either to differences 22 
in the assay protocol (in-vivo vs in-vitro) and/or differences in the nature of the fusion partner 23 
employed (VP16 and Gal4 DNA binding domain vs Glutathione S transferase) and the effects 24 
that this may have on the properties of the fusion protein. 25 
 26 
The initial deletion studies carried out on Pr55GAG showed that removal of 35 amino acids at 27 
the junction of MA (p17) and CA (p24) was sufficient to completely abolish the interaction 28 
with Vif pointing to the main site of interaction lying in this region of the protein. This result 29 
is partially consistent with that found in the earlier in-vitro study 5 where the MA-CA junction 30 
was also identified as a region involved in interacting with Vif. However the earlier study also 31 
identified a second site of interaction in the NC (p7) region of Pr55GAG that was not found in 32 
the current study 5. Again this difference may be due to the detailed differences in both the 33 
 10 
constructs and assay protocols employed and should not at this stage be taken to indicate the 1 
presence of only one interacting site between the two proteins in-vivo. 2 
 3 
Site directed mutagenesis of Vif to more specifically localise regions of the protein involved 4 
in the interaction with Pr55GAG revealed that the conserved tryptophan at position 21 was 5 
important. Change of this conserved position to arginine, isoleucine or tyrosine resulting in a 6 
greater than 80% drop in reporter gene expression in the two hybrid assay. By contrast 7 
substitution of the tryptophan with phenylalanine had no effect on the Vif - Pr55GAG 8 
interaction. These in-vivo results were corroborated by similar findings in an in-vitro GST 9 
pull down assay. This is interesting in the context of our earlier work showing that these same 10 
mutational changes when carried out on an infectious DNA clone  of HIV resulted in the same 11 
effects on the biological phenotype of virus produced in non-permissive cells 7. That is 12 
substitution with arginine, isoleucine or tyrosine resulted in a Vif –minus phenotype whereas 13 
substitution with phenylalanine gave a wild type Vif phenotype 7. More recent studies aimed 14 
at mapping the regions of Vif involved in overcoming the APOBEC3G/3F based inhibition of 15 
HIV replication have confirmed the importance of this conserved tryptophan 36. This study 16 
further argued that Trp21 mediated its effect on the APOBEC3G/3F inhibition by affecting the 17 
Vif directed degradation of APOBEC3G/3F, although no data on degradation were presented 18 
for this specific tryptophan 36. The results obtained on mutagenesis of the highly conserved 19 
YLAL residues that form part of the BC-box motif found towards the carboxy terminus of Vif 20 
were of interest in the context of the known involvement of this motif in APOBEC3G/3F 21 
degradation 28, 39. Despite it having been shown to be crucial for the formation of the complex 22 
with Cul5-EloBC involved in targeting APOBEC3G/3F for proteasomal based degradation 28, 23 
39, both single and double amino acid changes in the YLAL sequence had little or no effect on 24 
the Vif - Pr55GAG interaction.  25 
  26 
It has recently been shown that in the absence of functional Vif, APOBEC3G/3F will be 27 
incorporated into assembling viral capsids by interacting with the amino terminal region of 28 
NC in Pr55GAG 8, 24. The confirmation in the present study that Vif also interacts in-vivo with 29 
Pr55GAG raises the speculative possibility that in addition to its role in promoting the 30 
degradation of APOBEC3G/3F in non-permissive cells 9, 22, 23, 27, 33, 35, 38 Vif may also directly 31 
compete with APOBEC3G/3F for incorporation into the assembling virus particle. If further 32 
studies aimed at mapping more precisely the binding sites for Vif on Pr55GAG are able to 33 
confirm the earlier in-vitro studies indicating that both proteins have interaction sites that 34 
 11 
involve the NC region of Pr55GAG 5, 8, 24, then it will be important to establish whether or not it 1 
is the effects that Vif may have on the incorporation of APOBEC3G/3F into assembling 2 
virions that represent its primary route to relieving the APOBEC based block to viral 3 
replication in normal host cells for HIV.                                           4 
          5 
 12 
Figure Legends 1 
 2 
Fig 1: Analysis of Interactions between Vif, Protease and Pr55GAG using a GFP reporter 3 
in Mammalian Two-Hybrid Assays 4 
 5 
COS-1 cells (5 x 104 cells/well) were plated out in twelve well tissue culture plates to give 6 
~80% confluent monolayers after overnight incubation at 370C. These cells were co-7 
transfected with the Gal4 responsive GFP reporter ( pUAST-hrGFP-neo) plasmid and pM 8 
(Gal4 DNA binding domain) and pVP16 (Gal4 Activation domain) fusion constructs with Vif, 9 
Protease and Pr55GAG as described in Materials and Methods. A positive control transfection 10 
in which cells were co-transfected with reporter plasmid and fusion constructs of p53 and 11 
large T from SV40 which are known to interact in mammalian cells was included in all assays. 12 
The cell monolayers were examined by conventional light and UV microscopy three days 13 
after transfection and scored for reporter gene expression. Each panel of the figure consists of 14 
a pair of images, the left hand of which shows the cell monolayer viewed using conventional 15 
white light and the right hand of which shows reporter GFP expression in the same field 16 
viewed under UV light. The yellow size bar shown in panel A is 200nm and is provided to 17 
give an indication of magnification used in all panels. 18 
 19 
Panel A: Interaction between an activation domain fusion of Vif (AD-Vif) and a DNA 20 
binding domain fusion of Pr55GAG (BD- Pr55GAG). 21 
Panel B: Interaction between a DNA Binding domain fusion of Vif (BD-Vif) and an 22 
activation domain fusion of Pr55GAG (AD- Pr55GAG). 23 
Panel C: Interaction between an activation domain fusion of Vif (Ad-Vif) and a DNA binding 24 
domain fusion of Protease (BD-Protease). 25 
Panel D: Interaction between an activation domain fusion of Pr55GAG (AD- Pr55GAG) and a 26 
DNA binding domain fusion of Protease (BD-Protease). 27 
Panel E: Positive control showing interaction between p53 and the large T antigen of SV40 28 
virus. 29 
  30 
 13 
Fig 2: Analysis of the Interaction between Vif and Pr55GAG using a CAT reporter in the 1 
Mammalian Two-Hybrid Assay.  2 
 3 
COS-1 cells (~80% confluent) were co-transfected with the Gal4 responsive CAT reporter 4 
(pG5CAT) and various Vif and Pr55GAG fusion constructs as indicated under each column of 5 
the bar chart using the construct abbreviations given in Figure 3. At three days post 6 
transfection the cell monolayers were harvested and the level of reporter CAT expression 7 
assayed in cell free extracts using a CAT ELISA assay as described in Materials and Methods. 8 
The positive control used in these assays was co-transfection with fusion constructs 9 
expressing the interacting partners p53 and large T of SV40 virus. The negative control was 10 
co-transfection of cells with the two interaction plasmids carrying no fusion inserts. 11 
 12 
Fig 3: Schematic Diagram to show the Mutational Analysis of Vif and Pr55GAG 13 
employed to map interacting regions of the two proteins. 14 
 15 
Fig 4: Mammalian Two-Hybrid Analysis of Vif mutants to localise regions involved in 16 
interacting with Pr55GAG . 17 
 18 
COS-1 cells (~80% confluent) were co-transfected with the Gal4 responsive CAT reporter 19 
(pG5CAT), a Pr55GAG fusion construct in the pM Gal4 DNA binding domain vector and 20 
various Vif fusion mutants with the designations given in Figure 3 in the pVP16 Gal4 21 
activation domain vector. Negative controls in each case involved co-transfection of only the 22 
CAT reporter plasmid and Vif fusion under analysis. The specific plasmids used in each case 23 
are indicated under each column of the bar chart using the construct abbreviations given in 24 
Figures 3. At three days post transfection the cell monolayers were harvested and the level of 25 
reporter CAT expression assayed in cell free extracts using a CAT ELISA assay as described 26 
in Materials and Methods. 27 
 28 
Panel A: Shows results for the deletion mutants of Vif generated using inverse PCR 29 
mutagenesis (IPCRM) as described in Materials and Methods. 30 
Panel B: Shows results for a series of point mutations of the conserved tryptophan at amino 31 
acid 21 of Vif. These mutations were generated using site directed mutagenesis. 32 
 14 
Panel C: Shows the results obtained on mutagenesis of the highly conserved YLAL residues 1 
that form part of the BC-box motif near the carboxy terminus of Vif. These mutations were 2 
generated using site directed mutagenesis. 3 
 4 
Fig 5: Mammalian Two-Hybrid Analysis of Pr55GAG  mutants to localise regions 5 
involved in interacting with Vif. 6 
 7 
COS-1 cells (~80% confluent) were co-transfected with the Gal 4 responsive CAT reporter 8 
(pG5CAT), a Vif fusion construct in the pVP16 Gal4 activation domain vector and various 9 
Pr55GAG fusion mutants with the designations given in Figure 3 in the pM Gal 4 DNA binding 10 
domain vector. Negative controls in each case involved co-transfection of only the CAT 11 
reporter plasmid and Pr55GAG fusion under analysis. The specific plasmids used in each case 12 
are indicated under each column of the bar chart using the construct abbreviations given in 13 
Figure 3. At three days post transfection the cell monolayers were harvested and the level of 14 
reporter CAT expression assayed in cell free extracts using a CAT ELISA assay as described 15 
in Materials and Methods. 16 
 17 
Fig 6: In–vitro GST Pull down assay of interactions between Vif and Pr55GAG. 18 
 19 
This assay was carried out as described in Materials and Methods.20 
 15 
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  4 
rPr55GAG-DB and Vif-AD  GFP CAT
Pr55GAG (wt) + Vif (wt)  ++++ ++++ 
pM-BDPr55GAGMA-CA+Vif (wt) +++ +++ 
pM-BDPr55GAG∆MA-CA junction 35aa +Vif (wt) - - 
pM-BDPr55GAG∆MA +Vif (wt) - - 
pM-BDPr55GAG∆SP1LI +Vif (wt) ++++ ND 
pM-BDPr55GAG∆C-35aaCA +Vif (wt) ++++ ND 
pM-BDPr55GAG∆N-35aaMA +Vif (wt) ++++ ND 
pM-BDPr55GAGNC(p7)-SP1-LI(p6)+Vif (wt) - ND 
pM-BDPr55GAG∆LI +Vif (wt) ++++ ND 
pM-BDPr55GAGNC(p7) +Vif (wt) - ND 
Table 1  Summary of Mammalian Two-Hybrid Results Pr55GAG Mutants. 
 
A series of Pr55GAG deletion mutants in the Gal4 DNA Binding Domain vector were 
constructed by inverse PCR mutagenesis 30. Mutants were tested for their interaction with 
wild type (wt) Vif expressed as fusion with the VP16 Gal4 Activation Domain using GFP 
and CAT as a reporter. Comparison of  the expression of GFP or CAT reporter was done 
in relation to that given by a Wild type Pr55GAG and wild type Vif interaction which was 
considered to be 100% (++++).  Where ++++ = 100%; +++ = <75%; ++ = <50%; + = 
<25%; - = 0% and ND = not done. 
 
 
 23 
Bibliography 1 
 2 
1. Adekale MA, Cane PA, McCrae MA (2005) Changes in the Vif protein of HIV-1 3 
associated with the development of resistance to inhibitors of viral protease. J Med 4 
Virol 75: 195-201 5 
2. Arya SK, Guo C, Josephs SF, Wong-Staal F (1985) Trans-activator gene of human T-6 
lymphotropic virus type III (HTLV-III). Science 229: 69-73 7 
3. Baraz L, Hutoran M, Blumenzweig I, Katzenellenbogen M, Friedler A, Gilon C, 8 
Steinitz M, Kotler M (2002) Human immunodeficiency virus type 1 Vif binds the viral 9 
protease by interaction with its N-terminal region. J Gen Virol 83: 2225-2230 10 
4. Borman AM, Quillent C, Charneau P, Dauguet C, Clavel F (1995) Human 11 
immunodeficiency virus type 1 Vif- mutant particles from restrictive cells: role of Vif 12 
in correct particle assembly and infectivity. J Virol 69: 2058-2067 13 
5. Bouyac M, Courcoul M, Bertoia G, Baudat Y, Gabuzda D, Blanc D, Chazal N, 14 
Boulanger P, Sire J, Vigne R, Spire B (1997) Human immunodeficiency virus type 1 15 
Vif protein binds to the Pr55Gag precursor. J Virol 71: 9358-9365 16 
6. Bouyac M, Rey F, Nascimbeni M, Courcoul M, Sire J, Blanc D, Clavel F, Vigne R, 17 
Spire B (1997) Phenotypically Vif- human immunodeficiency virus type 1 is produced 18 
by chronically infected restrictive cells. J Virol 71: 2473-2477 19 
7. Boyce M, Willingmann P, McCrae M (1999) Identification of a functionally important 20 
amino acid residue near to the amino-terminus of the human immunodeficiency virus 21 
type 1 Vif protein. Virus Genes 19: 15-22 22 
8. Cen S, Guo F, Niu M, Saadatmand J, Deflassieux J, Kleiman L (2004) The interaction 23 
between HIV-1 Gag and APOBEC3G. J Biol Chem 279: 33177-33184 24 
9. Conticello SG, Harris RS, Neuberger MS (2003) The Vif protein of HIV triggers 25 
degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr Biol 13: 26 
2009-2013 27 
10. Desrosiers RC (1992) HIV with multiple gene deletions as a live attenuated vaccine 28 
for AIDS. AIDS Res Hum Retroviruses 8: 411-421 29 
11. Erickson-Viitanen S, Manfredi J, Viitanen P, Tribe DE, Tritch R, Hutchison CA, 3rd, 30 
Loeb DD, Swanstrom R (1989) Cleavage of HIV-1 gag polyprotein synthesized in 31 
vitro: sequential cleavage by the viral protease. AIDS Res Hum Retroviruses 5: 577-32 
591 33 
12. Fan L, Peden K (1992) Cell-free transmission of Vif mutants of HIV-1. Virology 190: 34 
19-29 35 
13. Fouchier RA, Simon JH, Jaffe AB, Malim MH (1996) Human immunodeficiency 36 
virus type 1 Vif does not influence expression or virion incorporation of gag-, pol-, 37 
and env-encoded proteins. J Virol 70: 8263-8269 38 
14. Gabuzda DH, Lawrence K, Langhoff E, Terwilliger E, Dorfman T, Haseltine WA, 39 
Sodroski J (1992) Role of vif in replication of human immunodeficiency virus type 1 40 
in CD4+ T lymphocytes. J Virol 66: 6489-6495 41 
15. Gabuzda DH, Li H, Lawrence K, Vasir BS, Crawford K, Langhoff E (1994) Essential 42 
role of vif in establishing productive HIV-1 infection in peripheral blood T 43 
lymphocytes and monocyte/macrophages. J Acquir Immune Defic Syndr 7: 908-915 44 
16. Gluzman Y (1981) SV40-transformed simian cells support the replication of early 45 
SV40 mutants. Cell 23: 175-182 46 
17. Harmache A, Russo P, Guiguen F, Vitu C, Vignoni M, Bouyac M, Hieblot C, Pepin M, 47 
Vigne R, Suzan M (1996) Requirement of caprine arthritis encephalitis virus vif gene 48 
for in vivo replication. Virology 224: 246-255 49 
 24 
18. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, 1 
Neuberger MS, Malim MH (2003) DNA deamination mediates innate immunity to 2 
retroviral infection. Cell 113: 803-809 3 
19. Hoglund S, Ohagen A, Lawrence K, Gabuzda D (1994) Role of vif during packing of 4 
the core of HIV-1. Virology 201: 349-355 5 
20. Imai Y, Nakamura M (1988) The importance of threonine-301 from cytochromes P-6 
450 (laurate (omega-1)-hydroxylase and testosterone 16 alpha-hydroxylase) in 7 
substrate binding as demonstrated by site-directed mutagenesis. FEBS Lett 234: 313-8 
315 9 
21. Lee TH, Coligan JE, Allan JS, McLane MF, Groopman JE, Essex M (1986) A new 10 
HTLV-III/LAV protein encoded by a gene found in cytopathic retroviruses. Science 11 
231: 1546-1549 12 
22. Liu B, Yu X, Luo K, Yu Y, Yu XF (2004) Influence of primate lentiviral Vif and 13 
proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of 14 
APOBEC3G. J Virol 78: 2072-2081 15 
23. Liu B, Sarkis PT, Luo K, Yu Y, Yu XF (2005) Regulation of Apobec3F and human 16 
immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase. J Virol 17 
79: 9579-9587 18 
24. Luo K, Liu B, Xiao Z, Yu Y, Yu X, Gorelick R, Yu XF (2004) Amino-terminal region 19 
of the human immunodeficiency virus type 1 nucleocapsid is required for human 20 
APOBEC3G packaging. J Virol 78: 11841-11852 21 
25. Madani N, Kabat D (1998) An endogenous inhibitor of human immunodeficiency 22 
virus in human lymphocytes is overcome by the viral Vif protein. J Virol 72: 10251-23 
10255 24 
26. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D (2003) Broad 25 
antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse 26 
transcripts. Nature 424: 99-103 27 
27. Marin M, Rose KM, Kozak SL, Kabat D (2003) HIV-1 Vif protein binds the editing 28 
enzyme APOBEC3G and induces its degradation. Nat Med 9: 1398-1403 29 
28. Mehle A, Goncalves J, Santa-Marta M, McPike M, Gabuzda D (2004) 30 
Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 31 
complex that promotes APOBEC3G degradation. Genes Dev 18: 2861-2866 32 
29. Oberste MS, Gonda MA (1992) Conservation of amino-acid sequence motifs in 33 
lentivirus Vif proteins. Virus Genes 6: 95-102 34 
30. Ochman H, Gerber AS, Hartl DL (1988) Genetic applications of an inverse 35 
polymerase chain reaction. Genetics 120: 621-623 36 
31. Sadowski I, Bell B, Broad P, Hollis M (1992) GAL4 fusion vectors for expression in 37 
yeast or mammalian cells. Gene 118: 137-141 38 
32. Sheehy AM, Gaddis NC, Choi JD, Malim MH (2002) Isolation of a human gene that 39 
inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418: 646-40 
650 41 
33. Sheehy AM, Gaddis NC, Malim MH (2003) The antiretroviral enzyme APOBEC3G is 42 
degraded by the proteasome in response to HIV-1 Vif. Nat Med 9: 1404-1407 43 
34. Simon JH, Gaddis NC, Fouchier RA, Malim MH (1998) Evidence for a newly 44 
discovered cellular anti-HIV-1 phenotype. Nat Med 4: 1397-1400 45 
35. Stopak K, de Noronha C, Yonemoto W, Greene WC (2003) HIV-1 Vif blocks the 46 
antiviral activity of APOBEC3G by impairing both its translation and intracellular 47 
stability. Mol Cell 12: 591-601 48 
 25 
36. Tian C, Yu X, Zhang W, Wang T, Xu R, Yu XF (2006) Differential requirement for 1 
conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective 2 
suppression of APOBEC3G and APOBEC3F. J Virol 80: 3112-3115 3 
37. Vasavada HA, Ganguly S, Germino FJ, Wang ZX, Weissman SM (1991) A contingent 4 
replication assay for the detection of protein-protein interactions in animal cells. Proc 5 
Natl Acad Sci U S A 88: 10686-10690 6 
38. Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, Yu XF (2003) Induction of APOBEC3G 7 
ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302: 8 
1056-1060 9 
39. Yu Y, Xiao Z, Ehrlich ES, Yu X, Yu XF (2004) Selective assembly of HIV-1 Vif-10 
Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and 11 
upstream cysteines. Genes Dev 18: 2867-2872 12 
40. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, Gao L (2003) The 13 
cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. 14 
Nature 424: 94-98 15 
41. Zheng YH, Irwin D, Kurosu T, Tokunaga K, Sata T, Peterlin BM (2004) Human 16 
APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 17 
replication. J Virol 78: 6073-6076 18 
 19 
 20 
